Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Genetic variation of pharmacogenomic VIP variants in Zhuang nationality of southern China

The Pharmacogenomics Journal volume 21, pages 60–68 (2021)Cite this article

Subjects

Abstract

Drug gene polymorphisms are strongly associated with disease. Previous studies have shown that the frequency of drug genes varies in different populations. At present, there are no reports about the polymorphism of the drug genome in the Zhuang population in southern China. This study conducted a pharmacogenomics study on the Zhuang population in southern China. Therefore, we conducted genotyping on 105 Zhuang samples, and compared the genotyping results with those of other 11 ethnic groups after statistical analysis. Our results show that, compared with the 11 populations in the HapMap data set, the differences between the CYP2E1 rs2070676 and CYP2D6 rs1065852 of the Zhuang nationality are the largest. This study fills in the blank of the drug genome information of the Zhuang nationality in southern China. The two sites of Rs2070676 (CYP2E1) and rs1065852 (CYP2D6) provide a reliable basis for the prediction of the efficacy of certain drugs. Its main purpose is to provide theoretical basis for safe drug use in the Zhuang region of southern China.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Allele frequencies in different populations.
Fig. 2: Distribution of alleles in different populations.
Fig. 3

Similar content being viewed by others

References

  1. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenom J. 2005;5:6–13.

    Article  CAS  Google Scholar 

  2. Jin T, Shi X, Li W, Wang H, Tian F, Kang L. Genetic polymorphisms of pharmacogenomic VIP variants in the Mongol of Northwestern China. BMC Genet. 2016;17:70.

    Article  Google Scholar 

  3. He Y, Yang H, Geng T, Feng T, Yuan D, Kang L, et al. Genetic polymorphisms of pharmacogenomic VIP variants in the lhoba population of southwest China. Int J Clin Exp Pathol. 2015;8:13293.

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Jin T, Zhao R, Shi X, He N, He X, Ouyang Y, et al. Genetic polymorphisms study of pharmacogenomic VIP variants in Han ethnic of China’s Shaanxi province. Environ Toxicol Pharmacol. 2016;46:27–35.

    Article  CAS  Google Scholar 

  5. Szekanecz Z, Meskó B, Poliska S, Váncsa A, Szamosi S, Végh E, et al. Pharmacogenetics and pharmacogenomics in rheumatology. High Blood Press Cardiovasc Prev Off J Ital Soc Hypertens. 2013;56:325–33.

    CAS  Google Scholar 

  6. Weinshilboum R. Inheritance and drug response. N Engl J Med. 2003;348:529–37.

    Article  Google Scholar 

  7. Evans WE. Pharmacogenomics: marshalling the human genome to individualise drug therapy. Gut. 2003;52(Suppl 2):ii10.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Administration FUD. FDA clears genetic test that advances personalized medicine: test helps determine safety of drug therapy. J Clin Eng. 2005;30:205–6.

    Google Scholar 

  9. Whirl-Carrillo M, Mcdonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012;92:414.

    Article  CAS  Google Scholar 

  10. Sangkuhl K, Berlin DS, Altman RB, Klein TE. PharmGKB: understanding the effects of individual genetic variants. Drug Metab Rev. 2008;40:539.

    Article  CAS  Google Scholar 

  11. Sim SC, Altman RB, Ingelmansundberg M. Databases in the area of pharmacogenetics. Hum Mutat. 2011;32:526–31.

    Article  CAS  Google Scholar 

  12. Badagnani I, Sorani M, Edwards RH, Brown C, Castro RA, Huang CC, et al. PharmGKB submission update: VI. PMT submissions of genetic variations in neurotransmitter transporters (SLC6, SLC17, and SLC18) to the PharmGKB network. Pharmacol Rev. 2006;58:5–6.

    Article  Google Scholar 

  13. Yunus Z, Liu L, Wang H, Zhang L, Li X, Geng T, et al. Genetic polymorphisms of pharmacogenomic VIP variants in the Kyrgyz population from northwest China. Gene. 2013;529:88–93.

    Article  CAS  Google Scholar 

  14. Yan M, Li D, Zhao G, Li J, Niu F, Li B, et al. Genetic polymorphisms of pharmacogenomic VIP variants in the Yi population from China. Gene. 2018;648:54–62.

    Article  CAS  Google Scholar 

  15. Wang L, Aikemu A, Yibulayin A, Du S, Geng T, Wang B, et al. Genetic polymorphisms of pharmacogenomic VIP variants in the Uygur population from northwestern China. BMC Genet. 2015;16:66.

    Article  Google Scholar 

  16. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007;39:347–51.

    Article  CAS  Google Scholar 

  17. Song MK, Lin FC, Ward SE, Fine JP. Composite variables: when and how. Nurs Res. 2013;62:45–49.

    Article  Google Scholar 

  18. Excoffier L, Laval G, Schneider S. Arlequin (version 3.0): an integrated software package for population genetics data analysis. Evol Bioinform Online. 2005;1(4A):47–50.

    CAS  Google Scholar 

  19. Falush D, Stephens M, Pritchard JK. Inference of population structure using multilocus genotype data: dominant markers and null alleles. Mol Ecol Notes. 2007;7:574–8.

    Article  CAS  Google Scholar 

  20. Gonzalez FJ. The 2006 Bernard B. Brodie Award Lecture. Cyp2e1. Drug Metab Dispos. 2007;35:597–8.

    Article  Google Scholar 

  21. Caro AA, Cederbaum AI. Oxidative stress, toxicology, and pharmacology of CYP2E1. Annu Rev Pharmacol Toxicol. 2004;44:27–42.

    Article  CAS  Google Scholar 

  22. Sompon W, Kamonrat P, Virapong P. Cytochrome P450 enzyme mediated herbal drug interactions (Part 2). Excli J. 2014;13:869–96.

    Google Scholar 

  23. Abdelmegeed MA, Banerjee A, Jang S, Yoo SH, Yun JW, Gonzalez FJ, et al. CYP2E1 potentiates binge alcohol-induced gut leakiness, steatohepatitis, and apoptosis. Free Radic Biol Med. 2013;65:1238–45.

    Article  CAS  Google Scholar 

  24. Lieber CS. The discovery of the microsomal ethanol oxidizing system and its physiologic and pathologic role. Drug Metab Rev. 2004;36:511–29.

    Article  CAS  Google Scholar 

  25. Liao L, Zhang H, Lai MP, Chen SL, Wu M, Shen N. Single-nucleotide polymorphisms and haplotype of CYP2E1 gene associated with systemic lupus erythematosus in Chinese population. Arthritis Res Ther. 2011;13:R11.

    Article  CAS  Google Scholar 

  26. Trafalis DT, Panteli ES, Grivas A, Tsigris C, Karamanakos PN. CYP2E1 and risk of chemically mediated cancers. Expert Opin drug Metab Toxicol. 2010;6:307–19.

    Article  CAS  Google Scholar 

  27. Chang LS, Hsu YW, Lu CC, Lo MH, Hsieh KS, Li SC, et al. CYP2E1 gene polymorphisms related to the formation of coronary artery lesions in Kawasaki disease. Pediatr Infect Dis J. 2017;36:1039.

    Article  Google Scholar 

  28. Shahabi HN, Westberg L, Melke J, Håkansson A, Belin AC, Sydow O, et al. Cytochrome P450 2E1 gene polymorphisms/haplotypes and Parkinson’s disease in a Swedish population. J Neural Transm. 2009;116:567–73.

    Article  Google Scholar 

  29. Polonikov AV, Ivanov VP, Solodilova MA. CYP2E1 gene promoter polymorphism -1293G>C increases the risk of essential hypertension in men with alcohol abuse. Bull Exp Biol Med. 2013;155:734–7.

    Article  CAS  Google Scholar 

  30. Wang L, Ren G, Li J, Zhu L, Niu F, Yan M, et al. Genetic polymorphism analysis of cytochrome P4502E1 (CYP2E1) in a Chinese Tibetan population. Medicine. 2017;96:e8855.

    Article  CAS  Google Scholar 

  31. Zhang C, Jiang X, Chen W, Li Q, Yun F, Yang X, et al. Population genetic difference of pharmacogenomic VIP gene variants in the Lisu population from Yunnan Province. Medicine. 2018;97:e13674.

    Article  Google Scholar 

  32. Brynne N, Dalén P, Alván G, Bertilsson L, Gabrielsson J. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. Clin Pharmacol Ther. 1998;63:529–39.

    Article  CAS  Google Scholar 

  33. Cronin-Fenton DP, Damkier P. Tamoxifen and CYP2D6: a controversy in pharmacogenetics. Adv Pharmacol. 2018;83:65–91.

    Article  CAS  Google Scholar 

  34. Niwa T, Yanai M, Matsumoto M, Shizuku M. Effect of cytochrome P450 (CYP) 2D6 genetic polymorphism on the inhibitory action of antidepressants on CYP2D6-mediated dopamine formation from p-Tyramine. J Pharm Pharm Sci. 2018;21:135–42.

    Article  Google Scholar 

  35. Vieira CP, Neves DV, Coelho EB, Lanchote VL. Effect of CYP2D6 poor metabolizer phenotype on stereoselective nebivolol pharmacokinetics. Drug Metab Lett. 2018;12:68–70.

    Article  CAS  Google Scholar 

  36. López-García MA, Feria-Romero IA, Serrano H, Rayo-Mares D, Fagiolino P, Vázquez M, et al. Influence of genetic variants of CYP2D6, CYP2C9, CYP2C19 and CYP3A4 on antiepileptic drug metabolism in pediatric patients with refractory epilepsy. Pharmacol Rep. 2017;69:504.

    Article  Google Scholar 

  37. Lu J, Fu J, Zhong Y, Chen P, Yang Q, Zhao Y, et al. The roles of apolipoprotein E3 and CYP2D6 (rs1065852) gene polymorphisms in the predictability of responses to individualized therapy with donepezil in Han Chinese patients with Alzheimer’s disease. Neurosci Lett. 2016;614:43–48.

    Article  CAS  Google Scholar 

  38. Sun CJ, Li L, Li XY, Zhang WY, Liu XW. Associations of polymorphisms of CYP2D6 and CYP2C9 with early onset severe pre-eclampsia and response to labetalol therapy. Arch Gynecol Obstet. 2018;298:125–32.

    Article  Google Scholar 

Download references

Acknowledgements

Thanks to those who provided blood samples from the Zhuang ethnic group in southern China, to all the medical staff and to all the authors who participated in the study.

Author information

Authors and Affiliations

  1. Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, School of Medicine, Northwest University, 229 Taibai North Road, Xi’an, 710069, China

    Yuanwei Liu, Haiyue Li, Keqing Cao, Jianfeng Liu, Yao Sun, Jiamin Wu, Zichao Xiong, Fanglin Niu, Jing Li & Tianbo Jin

  2. Key Laboratory of Molecular Mechanism and Intervention Research for Plateau Diseases of Tibet Autonomous Region, School of Medicine, Xizang Minzu University, Xianyang, 712082, Shaanxi, China

    Tianbo Jin

Authors
  1. Yuanwei Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Haiyue Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Keqing Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jianfeng Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yao Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jiamin Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Zichao Xiong
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Fanglin Niu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jing Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Tianbo Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tianbo Jin.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethics

The study participants were all informed and signed informed consents. The study was approved by Guangxi people’s hospital and Northwest university.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, Y., Li, H., Cao, K. et al. Genetic variation of pharmacogenomic VIP variants in Zhuang nationality of southern China. Pharmacogenomics J 21, 60–68 (2021). https://doi.org/10.1038/s41397-020-0177-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41397-020-0177-y

This article is cited by

Search

Advanced search

Quick links